12:29:34 EST Fri 15 Nov 2019
Enter Symbol
or Name
USA
CA



Login ID:
Password:
Save
Stagezero Life Sciences Ltd
Symbol SZLS
Shares Issued 227,232,793
Close 2019-08-07 C$ 0.13
Recent Sedar Documents

Stagezero Life CEO to present at ii6 Summit Aug. 8

2019-08-07 10:28 ET - News Release

Mr. James Howard-Tripp reports

STAGEZERO LIFE SCIENCES TO PRESENT AT II6 SUMMIT IN TORONTO

Stagezero Life Sciences Ltd.'s chairman and chief executive officer, James Howard-Tripp, will be presenting at the ii6 Summit on Thursday, Aug. 8, 2019, at the Omni King Edward Hotel in Toronto. The event, which is sponsored by InvestorIntel, gives CEOs an opportunity to present their companies to multiple self-directed, accredited investors.

"We look forward to presenting the Stagezero offering to this sophisticated group of investors and to explain our approach to early cancer detection through blood," said Mr. Howard-Tripp. "We are particularly excited to build greater awareness around our next-generation test, Aristotle, a test for the simultaneous detection of 10 discrete cancers from a single sample of blood."

About Stagezero Life Sciences Ltd.

Stagezero is dedicated to the early detection (stage 0) of cancer and multiple disease states through whole blood. Its next-generation test, Aristotle, is a multicancer panel for simultaneously screening for 10 cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle is built on the company's proven and proprietary sentinel principle technology platform, which was validated on 10,000 patients and used to develop the first liquid biopsy for colorectal cancer.

We seek Safe Harbor.

© 2019 Canjex Publishing Ltd. All rights reserved.